Literature DB >> 18829576

MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells.

Thales Papagiannakopoulos1, Alice Shapiro, Kenneth S Kosik.   

Abstract

MicroRNA dysregulation is observed in different types of cancer. MiR-21 up-regulation has been reported for the majority of cancers profiled to date; however, knowledge is limited on the mechanism of action of miR-21, including identification of functionally important targets that contribute to its proproliferative and antiapoptotic actions. In this study, we show for the first time that miR-21 targets multiple important components of the p53, transforming growth factor-beta (TGF-beta), and mitochondrial apoptosis tumor-suppressive pathways. Down-regulation of miR-21 in glioblastoma cells leads to derepression of these pathways, causing repression of growth, increased apoptosis, and cell cycle arrest. These phenotypes are dependent on two of the miR-21 targets validated in this study, HNRPK and TAp63. These findings establish miR-21 as an important oncogene that targets a network of p53, TGF-beta, and mitochondrial apoptosis tumor suppressor genes in glioblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829576     DOI: 10.1158/0008-5472.CAN-08-1305

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  297 in total

1.  miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.

Authors:  Arti B Gaur; Susan L Holbeck; Nancy H Colburn; Mark A Israel
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

3.  Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma.

Authors:  Alexander Baraniskin; Jan Kuhnhenn; Uwe Schlegel; Abdelouahid Maghnouj; Hannah Zöllner; Wolf Schmiegel; Stephan Hahn; Roland Schroers
Journal:  Neuro Oncol       Date:  2011-09-21       Impact factor: 12.300

Review 4.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 5.  Mechanisms of age-related cognitive change and targets for intervention: epigenetics.

Authors:  Kenneth S Kosik; Peter R Rapp; Naftali Raz; Scott A Small; J David Sweatt; Li-Huei Tsai
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-04-20       Impact factor: 6.053

Review 6.  microRNAs and EMT in mammary cells and breast cancer.

Authors:  Josephine A Wright; Jennifer K Richer; Gregory J Goodall
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-25       Impact factor: 2.673

7.  MicroRNAs in Cerebral Ischemia.

Authors:  Kai-Ying Lim; Jia-Hui Chua; Jun-Rong Tan; Priyadharshni Swaminathan; Sugunavathi Sepramaniam; Arunmozhiarasi Armugam; Peter Tsun-Hon Wong; Kandiah Jeyaseelan
Journal:  Transl Stroke Res       Date:  2010-12       Impact factor: 6.829

Review 8.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

9.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

Review 10.  MicroRNAs: history, biogenesis, and their evolving role in animal development and disease.

Authors:  M Bhaskaran; M Mohan
Journal:  Vet Pathol       Date:  2013-09-17       Impact factor: 2.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.